Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of Debridement-scaling on the Relief of Dry Eye Signs and Symptoms in Sjogren's Syndrome (TOYOTA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02203188
Recruitment Status : Completed
First Posted : July 29, 2014
Last Update Posted : December 19, 2014
Sponsor:
Collaborator:
Sjogren's Society of Canada
Information provided by (Responsible Party):
University of Waterloo

Brief Summary:
Sjogren's Syndrome is an autoimmune condition in which the body attacks its own glands in the body. Some of these glands are responsible for providing lubrication for the eye. As a result, individuals with Sjogren's Syndrome often experience dry eye. Recently, a study had shown that dry eye symptoms were improved by removing debris and old skin cells along the eyelid margin. This technique is called eyelid debridement-scaling. The purpose of this study is to determine how well this technique works in improving dry eye signs and symptoms in individuals with Sjogren's Syndrome.

Condition or disease Intervention/treatment Phase
Sjogren's Syndrome Procedure: Lid debridgement scaling Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 14 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Study Start Date : August 2014
Actual Primary Completion Date : November 2014
Actual Study Completion Date : November 2014

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Lid debridgement scaling
Perform lid debridgement scaling
Procedure: Lid debridgement scaling
No Intervention: Control
No Treatment



Primary Outcome Measures :
  1. Meibomian gland score (MGS) [ Time Frame: Baseline ]
    Prior to treatment (if applicable). Scale 0-3. 0: no secretion, 1: inspissated (toothpaste), 2: cloudy with debris, 3: clear

  2. Meibomian gland score (MGS) [ Time Frame: 1 month after baseline and/or treatment ]
    Scale 0-3. 0: no secretion, 1: inspissated (toothpaste), 2: cloudy with debris, 3: clear

  3. SICCA Ocular Staining Score [ Time Frame: Baseline ]
    Prior to treatment (if applicable). Based on corneal and conjunctival staining. Total scores range 0 to 12 with 0 being no staining and 12 being high staining.

  4. SICCA Ocular Staining Score [ Time Frame: 1 month after baseline and/or treatment ]
    Based on corneal and conjunctival staining. Total scores range 0 to 12 with 0 being no staining and 12 being high staining.

  5. Ocular Surface Disease Index Score (OSDI) [ Time Frame: Baseline ]
    Prior to treatment (if applicable). The OSDI is a questionnaire that consists of 12 questions about ocular irritation and the effect of dry eye on vision. For every question, participants check a score between 0 and 4, where 0 equals "none of the time" and 4 equals "all of the time". OSDI scores are calculated according to: OSDI = [(sum of scores for all questions answered)*100] / [(total number of questions answered)*4]. The possible range of the OSDI score is 0 to 100.

  6. Ocular Surface Disease Index Score (OSDI) [ Time Frame: 1 month after baseline/treatment ]
    The OSDI is a questionnaire that consists of 12 questions about ocular irritation and the effect of dry eye on vision. For every question, participants check a score between 0 and 4, where 0 equals "none of the time" and 4 equals "all of the time". OSDI scores are calculated according to: OSDI = [(sum of scores for all questions answered)*100] / [(total number of questions answered)*4]. The possible range of the OSDI score is 0 to 100.

  7. Meibomian gland yielding liquid secretions (MGYLS) [ Time Frame: Baseline ]
    Prior to treatment (if applicable). MGYLS is the number of glands with MGS grade 2 or higher.

  8. Meibomian gland yielding liquid secretions (MGYLS) [ Time Frame: 1 month after baseline/treatment ]
    MGYLS is the number of glands with MGS grade 2 or higher.

  9. Symptom Assessment iN Dry Eye score [ Time Frame: Baseline ]
    Prior to treatment (if applicable). A short questionnaire based on a visual analog scale (VAS) to quantify the frequency and severity of symptoms of dry eye syndrome. The "Symptom Assessment iN Dry Eye" (SANDE) questionnaire utilizes a 100 mm horizontal VAS technique to quantify patient symptoms of ocular dryness and/or irritation.

  10. Symptom Assessment iN Dry Eye score [ Time Frame: 1 month after baseline and/or treatment ]
    A short questionnaire based on a visual analog scale (VAS) to quantify the frequency and severity of symptoms of dry eye syndrome. The "Symptom Assessment iN Dry Eye" (SANDE) questionnaire utilizes a 100 mm horizontal VAS technique to quantify patient symptoms of ocular dryness and/or irritation.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   17 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Is at least 17 years of age and has full legal capacity to volunteer;
  • Has read and signed an information consent letter;
  • Is willing and able to follow instructions and maintain the appointment schedule;
  • Is diagnosed with Sjogren's Syndrome;
  • Meibomian gland score of ≤ 9 (out of 15);
  • OSDI ≥ 23;
  • Willing to maintain the use of OTC medications throughout the course of the study
  • Have not worn contact lenses within the past 3 years

Exclusion Criteria:

  • Is participating in any concurrent clinical or research study;
  • Has any known active* ocular disease and/or infection;
  • Has a systemic condition, other than Sjogren's Syndrome and its associated conditions, that in the opinion of the investigator may affect a study outcome variable;
  • Is using any systemic or topical medications, other than those indicated for Sjogren's Syndrome and its associated conditions, that in the opinion of the investigator may affect a study outcome variable;
  • Has known sensitivity to the diagnostic pharmaceuticals to be used in the study;
  • Is pregnant, lactating or planning a pregnancy at the time of enrolment;
  • Is aphakic;
  • Has undergone refractive error surgery; * For the purposes of this study, active ocular disease is defined as infection or inflammation which requires therapeutic treatment. Lid abnormalities (blepharitis, meibomian gland dysfunction, papillae), corneal and conjunctival staining and dry eye are not considered active ocular disease. Neovascularization and corneal scars are the result of previous hypoxia, infection or inflammation and are therefore not active.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02203188


Locations
Layout table for location information
Canada, Ontario
Centre for Contact Lens Research, University of Waterloo
Waterloo, Ontario, Canada, N2L 3G1
Sponsors and Collaborators
University of Waterloo
Sjogren's Society of Canada
Investigators
Layout table for investigator information
Principal Investigator: Lyndon Jones, PhD CCLR, University of Waterloo

Layout table for additonal information
Responsible Party: University of Waterloo
ClinicalTrials.gov Identifier: NCT02203188     History of Changes
Other Study ID Numbers: 20000
First Posted: July 29, 2014    Key Record Dates
Last Update Posted: December 19, 2014
Last Verified: December 2014

Additional relevant MeSH terms:
Layout table for MeSH terms
Syndrome
Sjogren's Syndrome
Dry Eye Syndromes
Disease
Pathologic Processes
Arthritis, Rheumatoid
Arthritis
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Xerostomia
Salivary Gland Diseases
Mouth Diseases
Stomatognathic Diseases
Lacrimal Apparatus Diseases
Eye Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases